Vadodara based drugmaker Alembic has posted a 63.8 per cent rise in net profit for the second quarter of the fiscal to Rs 21.77 crore primarily on robust sales growth in branded formulations and active pharmaceutical ingredients (APIs).Net sales for the quarter stood at Rs 363 crore.
The company's domestic branded formulations business grew 27 per cent on a year-on-year basis to Rs 207 crore in Q2 while the APIs segment posted a 33 per cent rise to Rs 100 crore. Alembic's generics business reported a modest rise of 10 per cent in sales to Rs 40 crore during the quarter, it said in a statement. Its key products Azithral, Wikoryl and Zeet registered a growth of more than 26 per cent each during July-September.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app